Incidence and clinical characteristics of zolbetuximab-induced nausea and vomiting in CLDN18.2-positive unresectable advanced or recurrent gastric cancer: a retrospective study

Abstract Background Zolbetuximab for CLDN18.2-positive advanced gastric cancer frequently causes chemotherapy-induced nausea and vomiting (CINV), particularly during the first infusion. Single-center studies in Japan have reported standardized infusion protocols and antiemetic strategies; however, t...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Yosuke Ando, Hiroki Banno, Satoe Yamaguchi, Akiko Ban, Kenji Katsuragawa, Ryo Sakurai, Yumiko Sato, Satoshi Nakamura, Toshinori Sasaki, Hirotaka Inoue, Satomi Kumazawa, Takuya Koyama, Saeko Harada, Etsuko Mishima, Hiroshi Matsuoka, Shigeki Yamada, Masayuki Miyazaki
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2026-04-01
Schriftenreihe:	Journal of Pharmaceutical Health Care and Sciences
Schlagworte:	Zolbetuximab CINV CLDN18.2 Gastric cancer
Online-Zugang:	https://doi.org/10.1186/s40780-026-00569-z
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!